Burning Rock Biotech (BNR)
(Delayed Data from NSDQ)
$3.23 USD
-0.25 (-7.10%)
Updated Sep 20, 2024 11:09 AM ET
After-Market: $3.42 +0.19 (5.88%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Burning Rock Biotech Limited Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 76 | 82 | 80 | 66 | NA |
Cost Of Goods | 25 | 27 | 23 | 18 | NA |
Gross Profit | 51 | 55 | 57 | 48 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 145 | 197 | 182 | 111 | 0 |
Income After Depreciation & Amortization | -94 | -142 | -125 | -63 | 0 |
Non-Operating Income | 3 | 2 | 0 | 1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -92 | -141 | -125 | -62 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -92 | -141 | -125 | -62 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -92 | -141 | -125 | -62 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -124 | -118 | -58 | 0 |
Depreciation & Amortization (Cash Flow) | 19 | 18 | 8 | 5 | NA |
Income After Depreciation & Amortization | -94 | -142 | -125 | -63 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.24 | 10.39 | 10.42 | 5.13 | NA |
Diluted EPS Before Non-Recurring Items | -9.00 | -13.60 | -12.00 | -10.50 | NA |
Diluted Net EPS (GAAP) | -9.00 | -13.60 | -12.00 | -10.50 | NA |
Fiscal Year end for Burning Rock Biotech Limited Sponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 18.65 | 17.40 | 17.29 | 17.49 | 20.17 |
Cost Of Goods | 5.52 | 5.53 | 6.14 | 5.71 | 6.32 |
Gross Profit | 13.13 | 11.87 | 11.15 | 11.78 | 13.85 |
SG&A, R&D, and Dept/Amort Expenses | 28.44 | 29.30 | 34.76 | 36.28 | 32.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.31 | -17.43 | -23.61 | -24.50 | -18.72 |
Non-Operating Income | 0.46 | 0.62 | 0.74 | 0.59 | 0.68 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -14.84 | -16.81 | -22.86 | -23.92 | -18.04 |
Income Taxes | 0.03 | 0.03 | 0.15 | 0.06 | 0.06 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -14.87 | -16.84 | -23.01 | -23.98 | -18.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -14.87 | -16.84 | -23.01 | -23.98 | -18.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 102.60 | 105.22 | 10.24 | 10.23 | 8.52 |
Diluted EPS Before Non-Recurring Items | -0.14 | -0.16 | -2.20 | -2.30 | -1.80 |
Diluted Net EPS (GAAP) | -0.14 | -0.16 | -2.30 | -2.30 | -1.80 |